PMA device
Genvisc 850
Channel-Markers Medical, LLC · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Sep 2, 2015, newest Sep 2, 2015Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Genvisc 850"
MAUDE reports
21
Brand "Genvisc 850", since 2015
PubMed studies
1
Mentioning "Genvisc 850"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Genvisc 850
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- GENVISC 850PMA
P140005 · Decided Sep 2, 2015 · 504 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Genvisc 850", any status and sponsor, newest update first.
No registered device study names "Genvisc 850".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Genvisc 850", and for the whole product code for context.
This brand
21 reports: 0 malfunction, 21 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- GENVISC 850Injury
3011402886-2022-00001 · Received Jun 3, 2022 · Event dated Mar 31, 2022
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bacterial Infection
- GENVISC 850Injury
3003184440-2020-00001 · Received Oct 31, 2020 · Event dated Sep 28, 2020
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Inflammation; Pain; Joint Swelling
- GENVISC 850Injury
3011402886-2020-00001 · Received Oct 31, 2020 · Event dated Sep 28, 2020
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Inflammation; Pain; Joint Swelling
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Genvisc 850"[tiab]. The summary above synthesizes these.
- A method for establishing class III medical device equivalence: sodium hyaluronate (GenVisc 850) for the treatment of knee osteoarthritis.
Doros G, Lavin PT, Daley M, et al. · Med Devices (Auckl) · 2016Review
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.